Loading...
01/10 16:14
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with significant revenue and membership growth, improved adjusted EBITDA, and a successful share repurchase program. Despite some competitive and regulatory risks, management expressed confidence in their strategic initiatives like Counterpart Health. Positive guidance for 2025 further supports a favorable outlook. The Q&A revealed optimism about growth and differentiation in the market, although some responses lacked clarity. Overall, the strong financial metrics and optimistic guidance suggest a positive stock price movement.
MA Membership Growth 30% year-over-year increase, driven by strong AEP and OEP enrollment seasons.
Total Revenue $457 million, a 33% year-over-year growth, driven by 30% Medicare Advantage membership growth.
Insurance Revenue $457 million, a 34% year-over-year increase, attributed to strong member retention and effective onboarding of new members.
Adjusted EBITDA $26 million, a 279% year-over-year increase, reflecting strong growth in membership and revenue.
Adjusted Net Income $25 million, a 322% year-over-year increase, driven by improved operational efficiency and revenue growth.
GAAP Net Loss Improved by $18 million year-over-year, resulting in a loss of $1 million.
Adjusted SG&A as a Percentage of Revenue 18%, a decrease of 360 basis points year-over-year, while absorbing increased growth and variable costs.
Insurance BER 86.1%, a modest increase year-over-year, but in-line with expectations due to the implementation of CA-enabled affiliate entity.
Cash, Cash Equivalents and Investments $391 million, reflecting a strong balance sheet despite impacts from stock buyback program.
Cash Flow Used in Operating Activities $16 million, impacted by working capital and timing dynamics.
Days in Claims Payable 37 days, a decrease of 22 days sequentially, reflecting normalization of claims inventory.
Clover Assistant: Released a new whitepaper showing how Clover Assistant helps better manage Congestive Heart Failure, leading to better care and fewer hospital visits.
Medicare Advantage Membership Growth: Achieved a 30% jump in MA membership, with a strong enrollment season contributing to this growth.
Insurance Revenue: Insurance revenue grew by 34% year-over-year to $457 million driven by strong AEP and OEP enrollment seasons.
Counterpart Health: Pushing forward with Counterpart Health to partner with others and bring Clover Assistant to more people.
Adjusted EBITDA: 279% increase year-over-year, reflecting strong operational efficiencies.
SG&A Improvement: Adjusted SG&A as a percentage of total revenue decreased to 18%, representing a 360 basis point improvement year-over-year.
Claims Payable: Days in claims payable decreased to 37 days, reflecting normalization of claims inventory.
4 Star PPO Plan: Positive CMS final rate notice for 2026, expected to enhance growth and profitability.
Growth Strategy: Plans to expand Clover Assistant’s reach and improve unit economics for new member cohorts.
Competitive Pressures: Clover Health faces competitive pressures in the Medicare Advantage market, necessitating a focus on maintaining strong member retention and effective onboarding of new members.
Regulatory Issues: The company is navigating the HCC v28 phase-in and is impacted by the recent CMS final rate notice for 2026, which could affect their financial performance.
Supply Chain Challenges: There are potential supply chain challenges related to the delivery of in-home care services, which are critical for their Clover Care Services division.
Economic Factors: Economic factors, including the overall healthcare market dynamics and potential changes in Medicare reimbursement rates, could impact Clover's financial performance.
Operational Risks: The company must manage operational risks associated with increased utilization levels in the back half of the year, which is typical for Medicare Advantage plans.
Cash Flow Management: Clover Health experienced cash flow used in operating activities of $16 million, indicating potential challenges in managing working capital and operational timing.
Medicare Advantage Membership Growth: 30% increase in MA membership year-over-year.
Revenue Growth: 33% increase in revenue year-over-year.
Adjusted EBITDA Growth: 279% increase in adjusted EBITDA year-over-year.
Clover Assistant Utilization: Clover Assistant is being used to manage care effectively, leading to better health outcomes.
Clover Care Services: Personalized in-home care visits for members, enhancing care management.
Counterpart Health Expansion: Partnerships to expand Clover Assistant's reach to more members.
4 Star Rating Impact: Positive impact expected from the 4 Star rating in 2026.
2025 MA Membership Guidance: Expected to average between 103,000 and 107,000 members.
2025 Insurance Revenue Guidance: Projected between $1.8 billion and $1.875 billion.
2025 Adjusted EBITDA Guidance: Increased to between $50 million and $70 million.
2025 Adjusted Net Income Guidance: Increased to between $50 million and $70 million.
Insurance BER Guidance: Expected to be within a range of 87% to 88%.
Share Repurchase Program: During the first quarter, Clover Health successfully repurchased 5 million shares of common stock, utilizing the remaining $80 million authorized under their buyback program announced in May of the previous year.
The earnings call presents a mixed picture. While there is strong membership and revenue growth, profitability and star ratings have been negatively impacted. The Q&A section indicates management's confidence in addressing cost challenges and leveraging strategic growth initiatives. However, lowered guidance for 2025 EBITDA and ongoing cost pressures temper the positive aspects. The lack of clear guidance improvement and financial strain from new members further contribute to a neutral sentiment, suggesting limited short-term stock price movement.
The earnings call reveals strong financial performance with significant revenue and membership growth, improved GAAP net loss, and adjusted EBITDA. Despite cost pressures from increased Part D utilization and new member integration, the company has managed to maintain operational efficiency and improve SG&A. The Q&A section indicates confidence in handling cost pressures and leveraging strategic growth opportunities. The positive response to the COPD white paper and plans for similar initiatives further support a positive outlook. Overall, the company's robust growth and strategic initiatives are likely to result in a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
